Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominic T Moore

Showing results (41-50 of 105) with videos related to

Pageof 11
Sort By:
The Oncologist|October 26, 2022
Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal CancerJonathan D Sorah, Dominic T Moore, Matthew J Reilley, et al.
Nanoscale|January 15, 2014
Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicityManish Sethi, Rohit Sukumar, Shrirang Karve, et al.
Journal of Thoracic Disease|March 15, 2021
The impact of pathologic staging of the hilar/mediastinal nodes on outcomes in patients with early-stage NSCLC receiving stereotactic body radiotherapyBrandon T Mullins, Dominic T Moore, M Patricia Rivera, et al.
Clinical Lung Cancer|April 11, 2018
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung CancerJuneko E Grilley-Olson, Jared Weiss, Anastasia Ivanova, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2006
Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapyThomas E Stinchcombe, David E Morris, Dominic T Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumorsStephanie B Hatch, Harry M Lightfoot, Christopher P Garwacki, et al.
Leukemia & Lymphoma|April 10, 2009
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survivalThomas C Shea, Anne W Beaven, Dominic T Moore, et al.
The Oncologist|September 24, 2025
Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancerJonathan D Sorah, Dominic T Moore, Matthew J Reilley, et al.
Gynecologic Oncology|January 8, 2017
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinomaStuart R Pierce, Jessica E Stine, Paola A Gehrig, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancerCarrie B Lee, Thomas E Stinchcombe, Dominic T Moore, et al.
Pageof 11

Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
The Oncologist|October 26, 2022
Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal CancerJonathan D Sorah, Dominic T Moore, Matthew J Reilley, et al.
Nanoscale|January 15, 2014
Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicityManish Sethi, Rohit Sukumar, Shrirang Karve, et al.
Journal of Thoracic Disease|March 15, 2021
The impact of pathologic staging of the hilar/mediastinal nodes on outcomes in patients with early-stage NSCLC receiving stereotactic body radiotherapyBrandon T Mullins, Dominic T Moore, M Patricia Rivera, et al.
Clinical Lung Cancer|April 11, 2018
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung CancerJuneko E Grilley-Olson, Jared Weiss, Anastasia Ivanova, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2006
Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapyThomas E Stinchcombe, David E Morris, Dominic T Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumorsStephanie B Hatch, Harry M Lightfoot, Christopher P Garwacki, et al.
Leukemia & Lymphoma|April 10, 2009
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survivalThomas C Shea, Anne W Beaven, Dominic T Moore, et al.
The Oncologist|September 24, 2025
Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancerJonathan D Sorah, Dominic T Moore, Matthew J Reilley, et al.
Gynecologic Oncology|January 8, 2017
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinomaStuart R Pierce, Jessica E Stine, Paola A Gehrig, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancerCarrie B Lee, Thomas E Stinchcombe, Dominic T Moore, et al.
Pageof 11